Date: 2015-09-09
Type of information: Licensing agreement
Compound: VIS513
Company: Visterra (USA - MA) Serum Institute of India (India)
Therapeutic area: Infectious diseases
Type agreement: licensing development manufacturing production commercialisation
Action mechanism: monoclonal antibody. VIS513 is a humanized monoclonal antibody that is designed to bind and potently neutralize all four serotypes of dengue virus. This antibody is targeting a conserved region on dengue virus domain III of the E protein that is present across all dengue virus serotypes. In preclinical studies, VIS513 binds and potently neutralizes all four serotypes of dengue virus and demonstrates protection of animals challenged with a lethal dose of dengue virus. The company’s preclinical studies of VIS513 in animal models have demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its potential use as a single administration treatment for dengue virus infection. Visterra is currently developing VIS513 as a single administration treatment for dengue virus infection incollaboration with Singapore’s Agency for Science, Technology and Research (A*STAR).
Disease: dengue fever
Details: * On September 9, 2015, Visterra, a clinical-stage biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics for infectious diseases, and Serum Institute of India Ltd. (Serum Institute), a global leader in vaccine development and manufacturing, announced that the companies have entered into a license agreement for the development, manufacture and commercialization of VIS513 in the Indian subcontinent countries. Under the terms of the agreement, Serum Institute receives an exclusive license to VIS513 for the Indian subcontinent, including India, Pakistan, Bangladesh, Nepal, Bhutan, Maldives, and Sri Lanka. The companies will establish a joint steering committee primarily to coordinate VIS513 development activities for the Indian subcontinent with the global development strategy. Following regulatory approval, Serum Institute will be responsible for commercializing VIS513 in the licensed territories.
Financial terms: Serum Institute will pay Visterra a US$ 5 million upfront payment, plus up to US$ 34 million based on the achievement of certain development and commercial milestones. Additionally, once VIS513 is commercialized, Visterra will be eligible to receive tiered, double-digit royalties based on net sales in the licensed territories. Serum Institute will fund and be responsible for the clinical development of VIS513 in the licensed territories, including the filing of regulatory applications.
Latest news:
